Mobile website
Archive > Volume 24 Issue 6 > 2017,24(6):595-600. DOI:10.3872/j.issn.1007-385X.2017.06.004 Prev Next
Basic Research
Tropism and differentiation of human umbilical cord derived mesenchymal stem cells to tumor transplanted by hepatocarcinama HepG2 cells in situ
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To study the tropism and differentiation of human umbilical cord derived mesenchymal stem cell (HUMSC) to HepG2 orthotopic hepatocarcinoma. Methods: The in vitro hepatic differentiation of HUMSCs was induced by a twostep protocol; the changes in mRNA and protein expression of hepatic alphafetoprotein (AFP) and albumin (ALB) at different time points were examined by Realtime PCR and western blotting; the tropism of HUMSCs stimulated by conditional culture medium with HepG2 cells was identified by transwell assay. Subcutaeousorthotopic transplantation was used to build the HepG2 orthotopic hepatocarcinoma model in athymic BALB/c nude mice. HUMSCs were labeled with MSC.CMVLuc or MSC.AFPLuc through lentivirus transduction before orthotopically injected into hepatic parenchyma; the tropism of MSC.CMVLuc to tumor location as well as the hepatic differentiation of MSC.AFPLuc in tumorbearing liver was monitored by using IVIS living imaging system. Results：The in vitro hepatic differentiation of HUMSCs was successfully induced in vitrowith morphological changes, and the mRNA and protein levels of AFP and ALB significantly elevated after the culture (P<0.05); the tropism of HUMSCs to HepG2 cells was in a dosedependent manner (P<001). MSC.CMVLuc, which injected intravenously, migrated to liver after 48 h; and the luciferase signal in the liver of rats was enhanced on day 5. MSC.AFPLuc developed hepatic differentiation after 24 h of in situ transplantation; at day 7 of posttransplantation, the activity of AFP promoter was at the highest, while, its activity was undetectable at day 9. Conclusion：It was confirmed the tropism and differentiation of HUMSCs to liver by in vitro and in vivo experiments. This study may provide a new strategy of target gene therapy for hepatocarcinoma by using MSCs.
Keywords:
Project Supported:
Supported by the National Natural Science Foundation of China（No.81400176，No.81402121）, and the Foundation for Applied Research and Advanced Technology of Tianjin （No.14JCYBJC23700）
Clc Number:
